EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience

Harish Gopalakrishna, Jiezhun Gu, Yi-Ju Li, Huiman Barnhart iD, Dina Halegoua-DeMarzio, Herbert L Bonkovsky, A Sidney Barritt, Jean P Molleston, Naga P Chalasani, Marwan Ghabril iD

Liver International · 2026-07 · 46 (7)

DOI: 10.1111/liv.70719 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 02.06.2026. Verfasst von Harish Gopalakrishna und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Chemical and Drug Induced Liver Injury, Immunologic Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD).

Methods

Using the Drug‐Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non‐IBD indications (but excluding corticosteroids). HLA allele associations were investigated.

Results

Among 1806 participants, 81 (4.5%) had IBD‐agent DILI: 31 biologics (27 infliximab), 35 immunomodulators (31 azathioprine/mercaptopurine), 14 aminosalicylates (11 sulfasalazine) and 1 small molecule (tofacitinib). Median age was 45 years with 75% female and 78% White. Patients with biologic‐DILI were younger, had longer latency (median 124 days), predominantly hepatocellular injury (78%) and mostly mild severity (74%) with no deaths and one chronic case. Immunomodulator‐DILI was mainly cholestatic or mixed, with jaundice in 57%; two were fatal, one required transplant and five became chronic. Aminosalicylate‐DILI had the shortest latency (median 40 days), was hepatocellular (57%) or cholestatic (36%), often with rash (50%) or pruritus (36%), mostly mild (64%), with two chronic cases. DILI phenotype was similar with IBD and non‐IBD indications. Multiple HLA alleles were associated with infliximab ( HLA‐DPB1*01:01 , HLA‐B*08:01 and HLA‐DQB1*02:01 ) azathioprine ( HLA‐DR3 , HLA‐DRB1*03:01 and HLA‐A*33:01) , mercaptopurine ( HLA‐A*11:01 and HLA‐B*37:01 ) and sulfasalazine ( HLA‐B*53:01 ) DILI, compared to population controls and other DILI cases.

Conclusions

Clinical features such as latency, injury pattern, jaundice and dermatologic findings help distinguish implicated agents and guide prognosis in suspected DILI from IBD therapies. HLA alleles may help identify individuals at higher DILI risk and support causality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesChemical and Drug Induced Liver InjuryImmunologic FactorsHumansFemaleMiddle AgedMaleAdultProspective StudiesInfliximabSulfasalazineMercaptopurineHLA AntigensAzathioprine

Substanzen

InfliximabSulfasalazineImmunologic FactorsMercaptopurineHLA AntigensAzathioprine

Autor:innen und Institutionen

  • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Duke University, Durham, North Carolina, USA.
  • Sidney Kimmel Medical College, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
  • Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Advocate Health Wake Forest Baptist, Winston-Salem, North Carolina, USA.
  • University of North Carolina, Chapel Hill, North Carolina, USA.

ORCID-Profile: Huiman Barnhart, Marwan Ghabril

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Gopalakrishna, H., Gu, J., Li, Y. J., Barnhart, H., Halegoua-DeMarzio, D., Bonkovsky, H. L., Barritt, A. S., Molleston, J. P., Chalasani, N. P., & Ghabril, M. (2026). Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience. Liver International, 46(7). https://doi.org/10.1111/liv.70719

Vancouver

Gopalakrishna H, Gu J, Li YJ, Barnhart H, Halegoua-DeMarzio D, Bonkovsky HL, et al. Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience. Liver International. 2026;46(7). doi:10.1111/liv.70719

BibTeX
@article{Gopalakrishna2026,
  author = {Gopalakrishna, Harish and Gu, Jiezhun and Li, Yi-Ju and Barnhart, Huiman and Halegoua-DeMarzio, Dina and Bonkovsky, Herbert L and Barritt, A Sidney and Molleston, Jean P and Chalasani, Naga P and Ghabril, Marwan},
  title = {Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {7},
  doi = {10.1111/liv.70719}
}
Kostenlos starten →